We are live on ! Find out more
KAM

Krensavage Asset Management Portfolio holdings

AUM $256M
1-Year Est. Return 69.63%
This Fund
S&P 500
This Quarter Est. Return
+7.79%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$324M
AUM Growth
+$9.58M
Cap. Flow
-$9.13M
Cap. Flow %
-2.82%
Top 10 Hldgs %
98.19%
Holding
14
New
–
Increased
4
Reduced
8
Closed
2

Top Buys

Rank Stock Value
1
EXEL icon
Exelixis
EXEL
+$5.16M
2
TARO
Taro Pharmaceutical Industries Ltd.
TARO
+$1.89M
3
VNDA icon
Vanda Pharmaceuticals
VNDA
+$321K
4
ENTA icon
Enanta Pharmaceuticals
ENTA
+$249K

Top Sells

Rank Stock Value
1
MCK icon
McKesson
MCK
+$10.8M
2
BIIB icon
Biogen
BIIB
+$2.16M
3
UTHR icon
United Therapeutics
UTHR
+$2.11M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$580K
5
CAH icon
Cardinal Health
CAH
+$303K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
1
United Therapeutics
UTHR
$25.8B
$53.4M 16.5%
192,048
-8,359
-4% -$2.11M
BIIB icon
2
Biogen
BIIB
$30B
$49M 15.15%
177,004
-7,644
-4% -$2.16M
REGN icon
3
Regeneron Pharmaceuticals
REGN
$78.5B
$43.4M 13.4%
60,103
-786
-1% -$580K
ALKS icon
4
Alkermes
ALKS
$8.22B
$36.6M 11.32%
1,401,783
-9,899
-0.7% -$237K
EXEL icon
5
Exelixis
EXEL
$13.3B
$34.3M 10.6%
2,138,039
+316,564
+17% +$5.16M
ENTA icon
6
Enanta Pharmaceuticals
ENTA
$366M
$27.7M 8.55%
594,818
+5,458
+0.9% +$249K
EMBC icon
7
Embecta
EMBC
$216M
$25.7M 7.95%
1,017,657
-6,543
-0.6% -$200K
CAH icon
8
Cardinal Health
CAH
$53.9B
$25.6M 7.9%
332,749
-3,993
-1% -$303K
TARO
9
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$18.7M 5.78%
644,664
+63,871
+11% +$1.89M
EGRX
10
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$3.36M 1.04%
114,825
-6,258
-5% -$199K
KOD icon
11
Kodiak Sciences
KOD
$2.6B
$3.32M 1.03%
463,598
-5,790
-1% -$41.5K
VNDA icon
12
Vanda Pharmaceuticals
VNDA
$307M
$2.55M 0.79%
345,290
+32,991
+11% +$321K
MCK icon
13
McKesson
MCK
$100B
– –
-31,913
Closed -$10.8M
NXTC icon
14
NextCure
NXTC
$16.8M
– –
-2,608
Closed -$86K

Similar funds

CIA
Corigliano Investment Advisers Raleigh, North Carolina $256M AUM 54.89% 1-Year Est. Return
2
2Xideas Kusnacht, Switzerland $255M AUM 0.46% 1-Year Est. Return
CIM
Caldwell Investment Management Toronto, Ontario, Canada $255M AUM 36.87% 1-Year Est. Return
JFG
Juno Financial Group Richmond, Virginia $255M AUM
PIP
Palisades Investment Partners Santa Monica, California $255M AUM 50.52% 1-Year Est. Return
LRIC
Long Road Investment Counsel Kalamazoo, Michigan $255M AUM 12.85% 1-Year Est. Return
GAMC
Garner Asset Management Corp Plano, Texas $255M AUM 22.93% 1-Year Est. Return
TIA
Tiemann Investment Advisors Menlo Park, California $255M AUM 21.35% 1-Year Est. Return

Krensavage Asset Management's Q4 2022 Portfolio in Review

As of Q4 2022, Krensavage Asset Management held 14 positions worth $324M, up 3.1% from $314M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Krensavage Asset Management's Q4 2022 filing shows 4 increased, 8 reduced and 2 closed positions. The largest sale was McKesson, an estimated $10.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Krensavage Asset Management added most to Exelixis in Q4 2022, an estimated $5.16M increase.
  • Krensavage Asset Management's biggest Q4 2022 reduction was Biogen, cutting an estimated $2.16M.
  • Krensavage Asset Management fully exited McKesson in Q4 2022, selling an estimated $10.8M.
  • Krensavage Asset Management's ten largest holdings make up 98% of its $324M portfolio in Q4 2022.
  • Krensavage Asset Management opened 0 new positions and closed 2 in Q4 2022.
  • Krensavage Asset Management's portfolio value rose 3.1% quarter-over-quarter to $324M.

Based on Krensavage Asset Management's 13F filing for Q4 2022, filed 15 Feb 2023.